Pemetrexed in malignant pleural mesothelioma and the clinical outcome.

摘要: Introduction:  Pemetrexed has emerged as standard chemotherapy for malignant pleural mesothelioma (MPM). Objectives:  MPMs at two Finnish University Hospitals during 7 years (2000–2006) were reviewed in order to evaluate the treatments, survival and prognostic factors. The results periods (before pemetrexed use 2000–2002 with 2003–2006) compared. Methods:  Data collected from individual patient records retrospectively, analysed. Results:  Altogether 197 patients diagnosed following histologies: 136 (69%) epithelioid, 19 (10%) sarcomatoid, 17 (9%) mixed, 25 (13%) not specified; 141 (72%) received treatment (five extrapleural pneumonectomy, 36 pleurectomy/decortication, 126 chemotherapy). Median was 12.9 months 1-, 2- 3-year survivals 51.8%, 21.8% 12.1%, respectively. Univariate analysis showed no significant difference between before or era (P = 0.124). receiving other had median of 16.7 15.3 months, independent factors histology asbestos exposure. Non-epithelioid yielded times higher risk dying than epithelioid. Asbestos exposure doubled dying, but only 2003–2006. Conclusions:  is beneficial selected patients, it changed outcome whole MPM population much perhaps anticipated. Patient groups various treatments symptomatic care reached comparable those reported trials, thus emphasising need better subtyping individualising treatment. Please cite this paper as: Knuuttila A, Salomaa E-R, Saikkonen S, Hurme S Salo J. clinical outcome. Clin Respir J 2012; 6: 96–103.